Animal and Veterinary Innovation Agenda
The world of human and animal health is making exciting advancements - harnessing the potential of new technologies, evolving understanding of biological and chemical processes, and increasingly recognizing the interconnectedness of human, animal, and environmental health.
In September 2023, FDA released the Animal and Veterinary Innovation Agenda (AVIA) to ensure the most robust product development pipelines that deliver the products needed to support veterinarians, animal owners, agricultural producers, the food system, and public health programs. FDA is committed to spur innovative technologies that we regulate, while ensuring that our work is science driven, risk-based, timely and flexible.
News
- December 21, 2023 - FDA Issues Final Guidance to Assist Sponsors of Animal Drugs for Minor Uses and Minor Species (MUMS)
- December 15, 2023 - FDA Seeks Public Input on Guidance for Priority Zoonotic Animal Drug Designation
- May 10, 2023 - FDA Announces Project to Provide Key Tool for Animal Biotechnology Developers
- May 1, 2023 - FDA Conditionally Approves First Drug for Anemia in Cats with Chronic Kidney Disease
- December 13, 2022 - FDA Provides for More Treatments for Dogs and Cats to Qualify for Minor Use Status
The Animal and Veterinary Innovation Agenda: What is it?
FDA published the first AVIA in September, 2023. This living document is a vision for how FDA can support and spur innovation to better protect human and animal health.
The AVIA lists four objectives and several supporting actions that will further position the agency for continued scientific and technological evolution while helping ensure that a robust variety of safe and effective animal health products is available to animal owners, producers, and veterinarians.
We developed the Veterinary Innovation Program (VIP) to help developers of certain novel products – typically smaller developers and startups – by providing greater certainty in the regulatory process, encouraging development and research, and supporting an efficient and predictable pathway to market. FDA is now adding new elements to VIP to facilitate new products coming to market.
We are also exploring how to identify and address unmet animal and veterinary needs and applying modern data systems and science to inform on-demand, data-driven decisions – which will help us more effectively respond to human and animal health emergencies like those that can arise from pandemics, natural disasters, armed conflicts overseas, or domestic human and animal food outbreaks.
We’re committed to reassessing and modifying FDA's animal and veterinary product review programs and processes to further support development of safe, effective new products; spur innovation; and adopt smart improvements to regulatory pathways for new products to reach the marketplace.
Sitting at the intersection of converging science, FDA's Center for Veterinary Medicine is uniquely positioned to tap into expertise in-house, across the FDA and across the government and other sectors.
We are focused on the future and ensuring we are prepared to regulate the products of tomorrow. As science evolves, we will evolve alongside it, by continually working to refine and improve our pre- and post-market regulatory pathways, identify potential human and animal health risks, and fill any gaps that may arise.